FCGR2B and central nervous system cancer: We previously reported that FcγRIIB expression was upregulated in advanced gliomas that correlated with poor survival especially in tumors with mesenchymal (MES) feature and wild type IDH1 [13], suggesting its role in suppressing immune responses in GBM.